Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dogwood Therapeutics, Inc.VIRI · Entity 6845 | Director | February 26, 2024 | February 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dogwood Therapeutics, Inc.
Report date February 26, 2024 · Filed February 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2034-02-26 | Direct | 2,917 |
Reported balance
After 2024-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-26 · Grant · Acquired 2,917 · Balance 2,917 F1: The stock option will vest 100% on February 26, 2025, one year following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest 100% on February 26, 2025, one year following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2024 Filed Feb 28, 2024 17:56 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 2,917 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-24-005676 · form4-02282024_050222.xml · derivative · entry 1 Burch Richard Alan · CIK 0001837084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,917 Underlying: Common Stock · 2,917 shares Expires 2034-02-26 F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 17:58 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001415889-23-009987 · form4-06202023_050630.xml · derivative · entry 1 Burch Richard Alan · CIK 0001837084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2033-06-15 F1 · derivative.exercise_date: The stock option will vest 100% on June 15, 2024, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 18:05 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007092 · form4-06302022_110636.xml · derivative · entry 1 Burch Richard Alan · CIK 0001837084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 18:59 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003156 · form4-06232021_110634.xml · derivative · entry 1 Burch Richard Alan · CIK 0001837084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.